STARTUP PROFILE

Motif Neurotech

COUNTRY
USA
FOUNDED
2022
CATEGORY
Neuromodulation
Developing minimally invasive, battery-free brain implants (DOT) that wirelessly stimulate brain circuits to treat treatment-resistant depression.
Visit website →
Market Notes · Biweekly

Track this company

Funding, launches and regulatory moves across the neurotech startup map.

Subscribed. Check your inbox to confirm.

•
Neurofounders Insights
$   Funding   -
Series A
MODALITY
Others
FORM FACTOR
Implant
INTERFACE DEPTH
Implantable
INDICATION
Psychiatry
TARGET USER
Patients
REGULATORY STAGE
Investigational
Motif Neurotech is differentiated by its tiny, battery-free, minimally invasive implant architecture for depression, targeting a gap between external psychiatric neuromodulation and larger implanted systems. Its hardware elegance is a strong narrative advantage, though clinical proof remains early.
•
Mentioned in Market Notes
MOST RECENT COVERAGE
#
11
BCI reaches a new scale
30 September – 13 October 2026

Motif Neurotech became the first investment of One Giant Leap Ventures, Rice University's new venture fund offering up to $500,000 per investment. The Rice spinout is developing a minimally invasive brain implant for treatment-resistant depression.

#
7
Measuring What Works
4 August – 18 August 2026

Motif Neurotech activated the first site of its RESONATE study, opening enrollment at the University of Iowa. The early feasibility trial tests the DOT, a blueberry-sized wirelessly powered implant that sits in the skull above the brain without touching it, delivering stimulation to a region linked to depression. The study will expand to eight sites across six cities, evaluating safety over 12 months in patients with treatment-resistant depression. Motif positions the device as a durable alternative to repeated TMS sessions.

Articles featuring
Motif Neurotech